8-K: REGENXBIO Reports Positive Progress in Gene Therapy Pipeline and First Quarter 2024 Financial Results

REGENXBIO announced its first quarter 2024 financial results and provided updates on its gene therapy programs, highlighting progress towards pivotal trials and regulatory filings.

Summary

• REGENXBIO reported its financial results for the first quarter of 2024, with a net loss of $63.3 million, or $1.38 per share, compared to a net loss of $66.7 million, or $1.53 per share, for the same period in 2023.
• The company's cash, cash equivalents, and marketable securities totaled $380.5 million as of March 31, 2024, which is expected to fund operations into 2026.
• Revenues for the quarter were $15.6 million, down from $19.1 million in the first quarter of 2023, primarily due to non-recurring milestone revenue and a slight decrease in Zolgensma royalty revenues.
• Research and development expenses decreased to $54.8 million from $58.5 million year-over-year, mainly due to reduced manufacturing and personnel costs.
• General and administrative expenses also decreased to $18.3 million from $22.6 million year-over-year, primarily due to reduced personnel costs.
• The company is on track to file a Biologics License Application (BLA) for RGX-121 in 2024 and is accelerating progress towards pivotal trial initiation for RGX-202 in Duchenne muscular dystrophy in late Q3 to early Q4 2024.
• Positive interim results from the ALTITUDE trial for diabetic retinopathy support plans for an End-of-Phase II meeting with the FDA in Q1 2025, with a pivotal trial expected to start in the first half of 2025.
• The company has selected dose level 2 as the pivotal dose for RGX-202, with new data showing 20.9% microdystrophin expression and a 90% reduction in serum creatinine kinase levels in the second patient at 3 months and 10 weeks respectively.
• REGENXBIO is expanding the AFFINITY DUCHENNE trial and expects to enroll up to seven patients at the pivotal dose by early Q3 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the company's strong cash position, progress in clinical trials, and positive interim data. The company is on track to meet key milestones and has a clear path forward. The reduction in operating expenses is also a positive sign.

Positives

• The company has a strong cash position of $380.5 million, providing a runway into 2026.
• There is significant progress in the clinical pipeline, with key milestones expected in 2024 and 2025.
• Positive interim data for RGX-202 in Duchenne and ABBV-RGX-314 in diabetic retinopathy support further development.
• The selection of dose level 2 for RGX-202 allows for rapid acceleration into pivotal development.
• The company is actively enrolling patients in expanded trials, indicating strong operational execution.
• The company is on track to file a BLA for RGX-121 in 2024, potentially leading to a Priority Review Voucher in 2025.
• The company is seeing reduced operating expenses due to reduced headcount and other cost-cutting measures.

Negatives

• Revenues decreased to $15.6 million from $19.1 million year-over-year, primarily due to non-recurring milestone revenue.
• Zolgensma royalty revenues decreased slightly from $16.1 million to $15.2 million year-over-year.
• The company reported a net loss of $63.3 million for the quarter, although this is an improvement from the $66.7 million loss in the same period last year.

Risks

• The company's future success depends on the successful completion of clinical trials and regulatory approvals.
• There are risks associated with the timing of enrollment, commencement, and completion of clinical trials.
• The company's financial performance is subject to fluctuations in revenue and expenses.
• The company's cash runway is based on current operational plans and excludes potential milestone payments from AbbVie and the monetization of a priority review voucher.
• There are risks associated with the development and launch of new products, as well as the ability to obtain and maintain intellectual property protection.

Future Outlook

REGENXBIO expects its cash balance to fund operations into 2026 and anticipates significant progress across its prioritized pipeline, including advancing the Duchenne program into the pivotal stage and filing a BLA for RGX-121 this year, as well as finalizing plans to initiate a pivotal program in diabetic retinopathy early next year.

Management Comments

• Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO, stated that the company is making remarkable progress on advancing products through late-stage development.
• Management believes that communication from the FDA continues to support the need for alternative gene therapies for rare diseases, including Duchenne.
• Management believes that new, positive biomarker data from the AFFINITY DUCHENNE trial demonstrates the potential of RGX-202 as a meaningful and differentiated treatment option for the Duchenne community.

Industry Context

The announcement highlights the ongoing development of gene therapies for rare and retinal diseases, a growing area of focus in the biotechnology industry. The success of Novartis' Zolgensma, which utilizes REGENXBIO's NAV Technology, underscores the potential of AAV-based gene therapies. The company's progress in Duchenne and diabetic retinopathy positions it as a key player in these therapeutic areas.

Comparison to Industry Standards

• REGENXBIO's progress in Duchenne muscular dystrophy with RGX-202 is comparable to other gene therapy companies such as Sarepta Therapeutics, which has also been developing gene therapies for Duchenne.
• The company's collaboration with AbbVie on ABBV-RGX-314 for retinal diseases places it in competition with companies like Roche and Regeneron, which have established treatments for wet AMD.
• The reported $295 million in global sales of Zolgensma by Novartis demonstrates the commercial potential of gene therapies based on REGENXBIO's technology, setting a benchmark for other companies in the space.
• The company's cash runway into 2026 is a positive sign, indicating financial stability compared to other biotech companies that may face near-term funding challenges.

Stakeholder Impact

• Shareholders will likely view the progress in clinical trials and the strong cash position positively.
• Employees may be impacted by the reduced headcount, but the company's overall progress could improve job security.
• Patients with Duchenne muscular dystrophy, diabetic retinopathy, and MPS II stand to benefit from the company's pipeline of gene therapies.
• The company's collaboration with AbbVie and other licensees indicates a positive impact on the broader biotechnology ecosystem.

Next Steps

• REGENXBIO plans to hold an end-of-Phase II meeting with the FDA in early Q3 2024 for RGX-202.
• The company expects to initiate the pivotal trial for RGX-202 in late Q3 to early Q4 2024.
• REGENXBIO plans to file a BLA for RGX-121 in 2024.
• The company expects to hold an end-of-Phase II meeting with the FDA in Q1 2025 for ABBV-RGX-314 in diabetic retinopathy.
• REGENXBIO expects to initiate the first pivotal trial for ABBV-RGX-314 in the first half of 2025.
• The company expects to share new program and data updates for the Phase II AAVIATE trial in Q3 2024.

Key Dates

Keywords

gene therapy, REGENXBIO, AAV Therapeutics, Duchenne muscular dystrophy, diabetic retinopathy, RGX-202, ABBV-RGX-314, RGX-121, clinical trials, BLA, FDA, Zolgensma, financial results